Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.32, which includes tax gains and does not compare to the analyst estimate of $1.26. Revenue for the quarter came in at $620.4 million versus the consensus estimate of $619.15 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.